drugset / Trial / NCT03383523
Relative Bioavailability Study of Emodepside IR-tablets and Solution
Phase 1
Completed
77 enrolled
Drugs for Neglected Diseases
Bayer · collabBill and Melinda Gates Foundation · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov identifier: NCT02661178)
Timeline
- Start
- 2017-10-26
- Primary completion
- 2018-03-26
- Completion
- 2018-03-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emodepside | Small molecule | 5 mg | — |
| Subject | Emodepside | Small molecule | 10 mg | — |